

Responsible Care®

Creating value. Sharing Value.

March 14, 2024

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400001
Scrip Code: 532504

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Symbol: NAVINFLUOR EQ

Dear Sir / Madam,

## Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations')

Pursuant to the amendment in Regulation 30 of SEBI LODR Regulations, this is to inform you that the Board of Directors of the Company at its Meeting held on today, has based on the recommendation of the Audit Committee, approved additional investment of ~₹250 Crores in Navin Fluorine Advanced Sciences Limited ('NFASL'), Wholly Owned Subsidiary, by subscribing to Non-Cumulative, Non-Convertible, Non-participating, Redeemable Preference Shares for repayment of the existing Inter Corporate Deposits and further business funding requirements of NFASL. The requisite details in this regard are provided in **Annexure A**.

This intimation is also being made available on the Company's website <a href="www.nfil.in">www.nfil.in</a>.

Kindly take this intimation on your record.

Thanking You,
Yours faithfully,
For NAVIN FLUORINE INTERNATIONAL LIMITED

Niraj B. Mankad President Legal and Company Secretary

Encl.: as above





Creating value. Sharing Value.

## **Annexure A**

| Sr.<br>No. | Particulars  | Details   |  |
|------------|--|---|--|
| 1.         | Name of the target entity, details in brief such as size, turnover etc.  | Navin Fluorine Advanced Sciences Limited  Authorised Share Capital: ₹1,000 Crores Paid-up Share Capital: ~₹590 Crores  As on March 31, 2023: Turnover: ~₹514 Crores Profit After Tax: ~₹68 Crores Net-worth: ~₹658 Crores   |  |
| 2.         | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | NFASL is related party of the Company being a Wholly Owned Subsidiary. Thereby, the subscription of Non-Cumulative, Non-Convertible, Non-participating, Redeemable Preference Shares of NFASL through rights issue is Related Party Transaction and the same is on arm's length basis.  The Promoters / promoter group / group companies are not interested in the transaction. |  |
| 3.         | Industry to which the entity being acquired belongs  | Chemicals   |  |
| 4.         | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)  | Repayment of the existing Inter Corporate Deposits and further business funding requirements of NFASL   |  |
| 5.         | Brief details of any governmental or regulatory approvals required for the acquisition   | Not Applicable  |  |
| 6.         | Indicative time period for completion of the acquisition   | Tentatively May 2024  |  |
| 7.         | Consideration - whether cash consideration or share swap or any other form and details of the same   | Cash consideration  |  |
| 8.         | Cost of acquisition and/or the price at which the shares are acquired  | ~₹250 Crores only   |  |
| 9.         | Percentage of shareholding / control acquired and / or number of shares acquired   | 100%  |  |





Creating value. Sharing Value.

10. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

NFASL has been incorporated on February 06, 2020 in India by the Company for greenfield projects in fluorochemicals. NFASL has commenced its commercial operation in the financial year 2022-2023. The turnover of NFASL as on March 31, 2023 was ~ ₹514 Crores.

\*\*\*\*\*